- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06284304
A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL (DESTINATION)
Trial design: A single centre phase II non-randomised study
Trial population: Men with intermediate risk localised prostate cancer
Recruitment target: 20 patients in total
Trial objectives:
- Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects
Secondary
- To assess levels of acute GU and GI toxicity (CTCAE)
- To assess levels of late GU and GI toxicity (CTCAE)
- To assess late sexual quality of life (expanded EPIC, IIEF-5)
- To assess biochemical relapse-free survival at 2 years
Trial treatment: All radiotherapy will be delivered on the MR-linac. Intraprostatic dose will be varied according to risk of local recurrence, based on mpMRI, PSA and histology. The whole prostate will receive 30 Gy in 5 fractions and the GTV plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary endpoint: Technical feasibility of treating prostate cancer with toxicity- minimising radiotherapy on an MR-linac
Secondary endpoint:
- Physician reported GU and gastrointestinal (GI) toxicity (CTCAE grade) at baseline and the end of treatment then at 4 weeks and 3 months post-treatment.
- Late toxicity (CTCAE v5.0) at 1 and 2 years post-treatment
- Patient-reported outcome measures (PROMs) from the EPIC-26, IPSS, and IIEF-5 questionnaires. Patients will be asked to complete PROMs at 4 weeks, 3 and 6 months, 1 and 2 years post treatment.
- PSA control and kinetics at 2 years post-treatment
Quality of life: EPIC-26 QoL will be measured at baseline, then at 4 weeks and 3, 6, 12 and 24 months from end of treatment. IIEF-5 will be completed at baseline and months 6, 12 and 24. IPSS will be measured at all time points.
Follow-up: Patients will be assessed at 6, 12 and 24 months and then as per standard of care.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Floris Pos, MD PhD
- Phone Number: +31 20 512 9111
- Email: f.pos@nki.nl
Study Contact Backup
- Name: Uulke van der Heide, PhD
- Phone Number: +31 20 512 9111
- Email: u.vd.heide@nki.nl
Study Locations
-
-
-
Amsterdam, Netherlands, 1066CX
- Recruiting
- Netherlands Cancer Institute
-
Contact:
- Floris Pos, MD PhD
- Phone Number: +31 20 512 9111
- Email: f.pos@nki.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men aged ≥18 years
- Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
- Gleason score 3+3, 3+4 or 4+3 (Grade groups 1, 2 or 3)
- MRI stage T2 or less (as staged by AJCC TNM 2018)
- MRI-visible tumour(s) of PIRADS v2 grade 3 or higher on T2 and diffusion-weighted imaging and/or dynamic contrast-enhanced imaging with concordant pathology
- Dominant lesion <50% of prostate on any axial slice and <50% total prostate volume
- PSA <20 ng/ml prior to starting ADT
- Patients can be concurrently treated with androgen deprivation therapy if this would be standard of care. LHRH analogues or Bicalutamide are permitted. ADT is not mandatory where this would usually be omitted.
- WHO Performance status 0-2
- Ability of the participant understand and the willingness to sign a written informed consent form.
- Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.
Exclusion Criteria:
- Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)
- IPSS 19 or higher
- High grade disease (GG3) occult to MRI-defined lesion
- Post-void residual >100 mls, where known
- Prostate volume >90cc
- Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up
- Unilateral or bilateral total hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging
- Previous pelvic radiotherapy
- Patients needing >6 months of ADT due to disease parameters.
- Previous invasive malignancy within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental radiotherapy treatment
SBRT 5x30Gy of whole prostate and isotoxic 45 Gy GTV plus intra-prostatic margin
|
5 fraction de-escalated dose SBRT protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical feasibility of treating prostate cancer with toxicity minimising radiotherapy on a MR-linac
Time Frame: after 1,5 week of treatment
|
To establish the technical feasibility of treating prostate cancer with tumour-escalated/normal prostate de-escalated dose radiotherapy on an MR-linac.
Feasiblity is defined as coverage of GTV boost D90% >42Gy on the post-treatment imaging.
|
after 1,5 week of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute GU toxicity
Time Frame: within 90 days after first radiation treatment
|
Physician-reported acute GU and GI toxicity according to the CTCAE v5.0.
|
within 90 days after first radiation treatment
|
Acute GI toxicity
Time Frame: within 90 days after first radiation treatment
|
Physician-reported acute GU and GI toxicity according to the CTCAE v5.0.
|
within 90 days after first radiation treatment
|
Late GU toxicity
Time Frame: After at least 90 days after the first radioation treatment up to 2 years
|
Physician-reported late GU and GI toxicity according to the CTCAE v5.0.
|
After at least 90 days after the first radioation treatment up to 2 years
|
Late GI toxicity
Time Frame: After at least 90 days after the first radioation treatment up to 2 years
|
Physician-reported late GU and GI toxicity according to the CTCAE v5.0.
|
After at least 90 days after the first radioation treatment up to 2 years
|
PROMs
Time Frame: 2 years
|
will be assessed using the International Prostate Symptom Score (IPSS) questionnaire, the EPIC-26 questionnaire and the IIEF-5 questionnaire.
|
2 years
|
Biochemical free survival
Time Frame: Up to 2 years
|
PSA control, biochemical failure/progression. Biochemical failure is defined a PSA nadir+ 2 ng/ml.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Floris Pos, MD PhD, The Netherlands Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N22DES
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on De-escalated radiotherapy
-
Sun Yat-sen UniversityRecruitingNasopharyngeal Carcinoma | IMMUNOTHERAPY | Radiotherapy; ComplicationsChina
-
Royal Marsden NHS Foundation TrustRecruitingProstate AdenocarcinomaUnited Kingdom
-
Royal Marsden NHS Foundation TrustCompletedLocally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers | Locally Advanced Thyroid CancersUnited Kingdom
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownStage III Non-Small Cell Lung CancerSingapore
-
Peter MacCallum Cancer Centre, AustraliaCompletedNon Small Cell Lung Cancer Stage IIIAustralia
-
The Netherlands Cancer InstituteCompletedHead and Neck CancerNetherlands
-
Centre hospitalier de l'Université de Montréal...M.D. Anderson Cancer Center; Lawson Health Research Institute; Jewish General...RecruitingHead and Neck Cancer | Oropharynx Cancer | Human Papilloma VirusCanada
-
AHS Cancer Control AlbertaRecruitingSmall Cell Lung CancerCanada
-
PfizerTerminatedParkinson's Disease With Motor FluctuationsUnited States
-
China National Center for Cardiovascular DiseasesRecruitingMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Bleeding | Angina Pectoris | Dual Antiplatelet Therapy | Coronary Artery Bypass GraftingChina